FLT3 and systemic mastocytosis: Midostaurin has been approved by the Food and Drug Administration (FDA) since April 2017 for the treatment of newly diagnosed adult AML patients with mutant FLT3-positive or adult patients with systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia (https://www.fda.gov/drugs/resources-information-approved-drugs/midostaurin) (access on 10 September 2020).